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INTRODUCTION 
Historical solar particle events (SPEs) provide context for some understanding of acute radiation exposure risk to 
astronauts traveling outside of low Earth orbit. Modeling of potential doses delivered to exploration crewmembers 
anticipates limited radiation-induced health impacts, including prodromal symptoms of nausea, emesis, and fatigue, 
but suggests that more severe clinical manifestations are unlikely. Recent large animal-model research in space-
analogs closely mimicking SPEs has identified coagulopathic events independent of the hematopoietic sequelae of 
higher radiation doses, similar in manifestation to disseminated intravascular coagulation (DIC).  We explored the 
challenges of clinical management of radiation-related clinical manifestations, using currently accepted modeling 
techniques and anticipated physiological sequelae, to identify medical capabilities needed to successfully manage 
SPE-induced radiation illnesses during exploration spaceflight. 
METHODS 
A literature review was undertaken to identify terrestrial management standards for radiation-induced prodromal 
syndromes and radiation-induced coagulopathy. Terrestrial management was compared to current spaceflight 
medical capabilities to identify gaps and highlight challenges involved in expanding capabilities for future 
spaceflight.  
RESULTS  
Most terrestrial treatment options for management of radiation-induced illnesses are unavailable in current 
spaceflight medical capabilities. While current onboard resources may be sufficient to manage some aspects of 
radiation-induced illness, effective treatment of all potential manifestations would require significant expansion of 
capabilities.  
DISCUSSION 
Expanded medical capabilities for the treatment of radiation-induced illnesses could be included aboard future 
exploration vehicles. However, this would require substantial research, time, and funding to reach flight readiness, 
and vehicle limitations may ultimately restrict such capabilities for exploration flight. Feasibility of expanded 
capabilities should be weighed against likelihood of significant SPEs and extensive mission design constraints. 
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